Pharmaceutical giant Daiichi Sankyo Co. said Tuesday it has reached an agreement to wholly acquire Plexxikon Inc., a California-based drugmaker, for $805 million (about ¥66 billion) to strengthen its research and development of cancer drugs.
The two companies have also agreed that Daiichi Sankyo will pay up to $130 million to the U.S. firm if Plexxikon succeeds in commercializing a late-stage oncology drug currently undergoing clinical tests, meaning the buyout price could total ¥76.6 billion.
Wednesday, March 02, 2011
Daiichi Sankyo to buy Plexxikon | The Japan Times Online
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment